GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes
- Conditions
- MeaslesMumpsRubellaVaricella
- First Posted Date
- 2006-07-13
- Last Posted Date
- 2008-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 330
- Registration Number
- NCT00351923
- Locations
- 🇩🇪
GSK Investigational Site, Worms, Rheinland-Pfalz, Germany
A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma Control
- Conditions
- Asthma
- Interventions
- Drug: salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement trainingDrug: salmeterol/fluticasone propionate 50/250 µg
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 274
- Registration Number
- NCT00351143
- Locations
- 🇨🇭
GSK Investigational Site, Worb, Switzerland
Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma
- First Posted Date
- 2006-07-11
- Last Posted Date
- 2013-04-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 75
- Registration Number
- NCT00350727
A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients
- Conditions
- Type 2 Diabetes MellitusDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2006-07-07
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 256
- Registration Number
- NCT00349427
- Locations
- 🇨🇳
GSK Investigational Site, Tianjin, China
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
- First Posted Date
- 2006-07-07
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 223
- Registration Number
- NCT00349349
The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2016-12-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 654
- Registration Number
- NCT00347360
- Locations
- 🇺🇸
GSK Investigational Site, Milwaukee, Wisconsin, United States
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
- Conditions
- Neoplasms, Breast
- Interventions
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 189
- Registration Number
- NCT00347919
- Locations
- 🇬🇧
GSK Investigational Site, Plymouth, United Kingdom
Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis
- Conditions
- Hepatitis B, ChronicCirrhosisFibrosisChronic Hepatitis B
- Interventions
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 155
- Registration Number
- NCT00347009
- Locations
- 🇻🇳
GSK Investigational Site, Ho Chi Minh City, Vietnam
SB-742457 And Donepezil In Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2009-06-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 200
- Registration Number
- NCT00348192
- Locations
- 🇬🇧
GSK Investigational Site, West of Scotland Science Park, Glasgow, United Kingdom
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: Rosiglitazone Extended Release 2mgDrug: Rosiglitazone Extended Release 8mgOther: PlaceboOther: Donepezil
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2017-11-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1496
- Registration Number
- NCT00348309
- Locations
- 🇨🇭
GSK Investigational Site, Zuerich, Switzerland